Showing results (1861-1870 of 1,877) with videos related to

Sort By:
Pageof 188
Nature Communications|January 26, 2018
Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium lepraeAndrej Benjak, Charlotte Avanzi, Pushpendra Singh, et al.
Annals of Intensive Care|June 5, 2021
Mental health and stress among ICU healthcare professionals in France according to intensity of the COVID-19 epidemicAlexandra Laurent, Alicia Fournier, Florent Lheureux, et al.
International Journal of Cancer|October 9, 2016
Identification of miRSNPs associated with the risk of multiple myelomaAngelica Macauda, Diego Calvetti, Giuseppe Maccari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug RegistrationKenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Blood|August 24, 2016
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHDRaphael Carapito, Nicolas Jung, Marius Kwemou, et al.
Cancer Discovery|April 3, 2023
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant LeukemiaMarie Sabatier, Rudy Birsen, Laura Lauture, et al.
International Journal of Cancer|November 5, 2020
Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survivalOmbretta Melaiu, Angelica Macauda, Juan Sainz, et al.
Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.
Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Pageof 188